These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 16293957)

  • 21. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.
    Varga J
    Curr Rheumatol Rep; 2003 Apr; 5(2):145-6. PubMed ID: 12628045
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endogenous endothelin.
    Carteaux JP; Roux S; Siaghy M; Schjöth B; Dolofon P; Bechamps Y; Mertes PM; Villemot JP
    Eur J Cardiothorac Surg; 1999 Mar; 15(3):346-52. PubMed ID: 10333034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of pulmonary arterial hypertension: a step forward.
    Sharma S
    Chest; 2003 Jul; 124(1):8-11. PubMed ID: 12853493
    [No Abstract]   [Full Text] [Related]  

  • 25. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.
    Karavolias GK; Georgiadou P; Gkouziouta A; Kariofillis P; Karabela G; Tsiapras D; Sbarouni E; Chaidaroglou A; Degiannis D; Adamopoulos S; Voudris V
    Expert Opin Ther Targets; 2010 Dec; 14(12):1283-9. PubMed ID: 20958219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.
    Sitbon O; Gressin V; Speich R; Macdonald PS; Opravil M; Cooper DA; Fourme T; Humbert M; Delfraissy JF; Simonneau G
    Am J Respir Crit Care Med; 2004 Dec; 170(11):1212-7. PubMed ID: 15317666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombotic microangiopathic nephropathy, pulmonary hypertension and nephromegaly: case report of a patient treated with endothelin receptor antagonist.
    Losito A; Pittavini L; Covarelli C
    Clin Nephrol; 2012 Feb; 77(2):164-70. PubMed ID: 22257549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival with first-line bosentan in patients with primary pulmonary hypertension.
    McLaughlin VV; Sitbon O; Badesch DB; Barst RJ; Black C; Galiè N; Rainisio M; Simonneau G; Rubin LJ
    Eur Respir J; 2005 Feb; 25(2):244-9. PubMed ID: 15684287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study].
    Castro G
    Rev Port Cardiol; 2001 Nov; 20(11):1151-2. PubMed ID: 11826707
    [No Abstract]   [Full Text] [Related]  

  • 30. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension.
    Perez-Villa F; Cuppoletti A; Rossel V; Vallejos I; Roig E
    Clin Transplant; 2006; 20(2):239-44. PubMed ID: 16640533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease.
    Valerio G; Bracciale P; Grazia D'Agostino A
    Ther Adv Respir Dis; 2009 Feb; 3(1):15-21. PubMed ID: 19293199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bosentan: a dual endothelin receptor antagonist.
    Rubin LJ; Roux S
    Expert Opin Investig Drugs; 2002 Jul; 11(7):991-1002. PubMed ID: 12084009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bosentan in pulmonary arterial hypertension secondary to scleroderma.
    Joglekar A; Tsai FS; McCloskey DA; Wilson JE; Seibold JR; Riley DJ
    J Rheumatol; 2006 Jan; 33(1):61-8. PubMed ID: 16395751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome.
    Christensen DD; McConnell ME; Book WM; Mahle WT
    Am J Cardiol; 2004 Jul; 94(2):261-3. PubMed ID: 15246919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.
    Hirono K; Yoshimura N; Taguchi M; Watanabe K; Nakamura T; Ichida F; Miyawaki T
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):346-51. PubMed ID: 20434177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K; Jakrapanichakul D; Sompradikul S
    J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined endothelin receptor antagonist and transcatheter interventional therapy of patent ductus arteriosus with severe pulmonary artery hypertension.
    Ussia GP; Mulè M; Caruso E; Aiello R; Tamburino C
    Int J Cardiol; 2007 Apr; 116(3):427-9. PubMed ID: 16875749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan.
    Kiakouama L; Cottin V; Etienne-Mastroïanni B; Khouatra C; Humbert M; Cordier JF
    Eur Respir J; 2010 Jul; 36(1):202-4. PubMed ID: 20595165
    [No Abstract]   [Full Text] [Related]  

  • 39. Bosentan for mild pulmonary vascular disease in ASD patients (the BOMPA trial): a double-blind, randomized controlled, pilot trial.
    Van De Bruaene A; Jansen K; De Meester P; Delcroix M; Voigt JU; Gabriels C; Moons P; Budts W
    Int J Cardiol; 2013 Oct; 168(5):5081-2. PubMed ID: 23972964
    [No Abstract]   [Full Text] [Related]  

  • 40. [Endothelin].
    Maeda S; Miyauchi T; Goto K
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():112-6. PubMed ID: 16895176
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.